Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial
- PMID: 16413875
- DOI: 10.1016/S0140-6736(05)67861-0
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial
Abstract
Background: The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by post-infarction left-ventricular (LV) dysfunction. Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure.
Methods: We did a randomised, double-blind, placebo-controlled study in 67 patients from whom we harvested bone marrow 1 day after successful percutaneous coronary intervention for STEMI. We assigned patients optimum medical treatment and infusion of placebo (n=34) or BMSC (n=33). Our primary endpoint was the increase in LV ejection fraction and our secondary endpoints were change in infarct size and regional LV function at 4 months' follow-up, all assessed by MRI. We assessed changes in myocardial perfusion and oxidative metabolism with serial 1-[11C]acetate PET. Analyses were per protocol. This study is registered with , number NCT00264316.
Findings: Mean global LV ejection fraction 4 days after percutaneous coronary intervention was 46.9% (SD 8.2) in controls and 48.5% (7.2) in BMSC patients, and increased after 4 months to 49.1% (10.7) and 51.8% (8.8; OR for treatment effect 1.036, 95% CI 0.961-1.118, p=0.36). Compared with placebo infusion, BMSC transfer was associated with a significant reduction in myocardial infarct size (BMSC treatment effect 28%, p=0.036) and a better recovery of regional systolic function. Myocardial perfusion and metabolism increased similarly in both groups. We noted no complications associated with BMSC transfer and all but one patient in the BMSC group completed the 4 months' follow-up.
Interpretation: Intracoronary transfer of autologous bone marrow cells within 24 h of optimum reperfusion therapy does not augment recovery of global LV function after myocardial infarction, but could favourably affect infarct remodelling.
Comment in
-
Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk.Lancet. 2006 Jan 14;367(9505):87-8. doi: 10.1016/S0140-6736(05)67895-6. Lancet. 2006. PMID: 16413856 No abstract available.
-
Autologous bone-marrow stem cells for myocardial infarction.Lancet. 2006 Jul 1;368(9529):27. doi: 10.1016/S0140-6736(06)68963-0. Lancet. 2006. PMID: 16815373 No abstract available.
Similar articles
-
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.Lancet. 2004 Jul 10-16;364(9429):141-8. doi: 10.1016/S0140-6736(04)16626-9. Lancet. 2004. PMID: 15246726 Clinical Trial.
-
Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction.Am J Cardiol. 2009 Nov 15;104(10):1336-42. doi: 10.1016/j.amjcard.2009.06.057. Epub 2009 Sep 25. Am J Cardiol. 2009. PMID: 19892047 Clinical Trial.
-
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.Circulation. 2006 Mar 14;113(10):1287-94. doi: 10.1161/CIRCULATIONAHA.105.575118. Epub 2006 Mar 6. Circulation. 2006. PMID: 16520413 Clinical Trial.
-
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.Am Heart J. 2011 Oct;162(4):671-7. doi: 10.1016/j.ahj.2011.06.019. Am Heart J. 2011. PMID: 21982659 Review.
-
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.Eur Heart J. 2014 Apr;35(15):989-98. doi: 10.1093/eurheartj/eht372. Epub 2013 Sep 11. Eur Heart J. 2014. PMID: 24026778 Free PMC article. Review.
Cited by
-
Acute myocardial infarction does not affect functional characteristics of adipose-derived stem cells in rats, but reduces the number of stem cells in adipose tissue.Cell Tissue Res. 2015 Dec;362(3):623-32. doi: 10.1007/s00441-015-2239-z. Epub 2015 Jul 23. Cell Tissue Res. 2015. PMID: 26202892 Free PMC article.
-
Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart.Theranostics. 2015 Jan 1;5(2):196-205. doi: 10.7150/thno.7976. eCollection 2015. Theranostics. 2015. PMID: 25553108 Free PMC article.
-
Tracking cells implanted into cynomolgus monkeys (Macaca fascicularis) using MRI.Exp Anim. 2016 Jul 29;65(3):311-8. doi: 10.1538/expanim.15-0125. Epub 2016 Apr 11. Exp Anim. 2016. PMID: 27062993 Free PMC article.
-
Extracellular vesicles in cardiac repair and regeneration: Beyond stem-cell-based approaches.Front Cell Dev Biol. 2022 Sep 2;10:996887. doi: 10.3389/fcell.2022.996887. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36120584 Free PMC article. Review.
-
Cardiac tissue engineering and regeneration using cell-based therapy.Stem Cells Cloning. 2015 May 14;8:81-101. doi: 10.2147/SCCAA.S54204. eCollection 2015. Stem Cells Cloning. 2015. PMID: 25999743 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical